EQUE-CEL, A NOVEL FULLY HUMAN BCMA-TARGETING CAR-T THERAPY IN PATIENTS WITH HIGH RISK NEWLY DIAGNOSED MULTIPLE MYELOMA

EHA Library, Lijuan Chen, 422310

PHASE 1 STUDY OF ANITOCABTAGENE AUTOLEUCEL FOR THE TREATMENT OF PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA: RESULTS FROM AT LEAST 1-YEAR FOLLOW-UP IN ALL PATIENTS

EHA Library, Matthew Frigault, 422311

IDECABTAGENE VICLEUCEL (IDE-CEL) IN PATIENTS (PTS) WITH CLINICAL HIGH-RISK EARLY RELAPSE MULTIPLE MYELOMA (MM) WITHOUT FRONT-LINE (1L) AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT): KARMMA-2 COHORT 2B

EHA Library, Xavier Leleu, 422312

PHASE 2 STUDY OF FULLY HUMAN BCMA-TARGETING CAR-T CELLS (ZEVORCABTAGENE AUTOLEUCEL) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Wenming Chen, 422313

CEVOSTAMAB IN PATIENTS WITH RRMM WHO ARE TRIPLE-CLASS REFRACTORY AND HAVE RECEIVED A PRIOR BCMA-TARGETED ADC OR CAR T-CELL: INITIAL RESULTS FROM THE PHASE I/II CAMMA 2 STUDY

EHA Library, Shaji Kumar, 422314

EFFICACY, SAFETY, AND DETERMINATION OF RP2D OF ABBV-383, A BCMA BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM).

EHA Library, Katja Weisel, 422315

LINVOSELTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA IN THE LINKER-MM1 STUDY: DEPTH AND DURABILITY OF RESPONSE AT 14-MONTH MEDIAN FOLLOW-UP

EHA Library, Suzanne Lentzsch, 422316

OUTCOMES OF PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FOLLOWING EARLY PROGRESSION AFTER IDE-CEL THERAPY: AN IFM STUDY FROM THE DESCAR-T REGISTRY

EHA Library, Cayla Sarah, 422317

RESULTS FROM DREAMM-7 A RANDOMIZED PHASE 3 STUDY OF BELANTAMAB MAFODOTIN + BORTEZOMIB, AND DEXAMETHASONE VS DARATUMUMAB + BORTEZOMIB, AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, María-Victoria Mateos, 422318

SPATIAL TRANSCRIPTOMIC CHARACTERISATION OF THE BONE MARROW LANDSCAPE

EHA Library, Rosalin Cooper, 422319

DEVELOPMENT AND EVALUATION OF A NOVEL CAR-T CELL THERAPY AGAINST CALRETICULIN MUTANT NEOPLASMS

EHA Library, Alexandros Rampotas, 422320

ANALYSIS OF MOLECULAR MECHANISMS AND PREDICTIVE BIOMARKERS OF DISEASE TRANSFORMATION IN POLYCYTHEMIA VERA

EHA Library, Michael Grunwald, 422321

UPDATED LONG-TERM RESULTS FROM THE PHASE 2 REVIVE STUDY INVESTIGATING THE HEPCIDIN MIMETIC RUSFERTIDE IN POLYCYTHEMIA VERA PATIENTS (PTS): HEMATOCRIT CONTROL AND THERAPEUTIC PHLEBOTOMY (TP) FREQUENCY

EHA Library, Kristen Pettit, 422322

JAK2V617F MOLECULAR RESPONSE CORRELATES WITH EVENT-FREE SURVIVAL IN AN EARLY POLYCYTHEMIA VERA POPULATION

EHA Library, Jean-Jacques Kiladjian, 422323

PELABRESIB PLUS RUXOLITINIB COMBINATION THERAPY IN JAK INHIBITOR-NAÏVE PATIENTS WITH MYELOFIBROSIS IN THE MANIFEST-2 STUDY: PRELIMINARY EVIDENCE OF BONE MARROW RECOVERY

EHA Library, Raajit K Rampal, 422324

SAFETY AND EFFICACY OF PELABRESIB IN COMBINATION WITH RUXOLITINIB FOR JAK INHIBITOR TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS: LATEST DATA FROM THE PHASE 3 MANIFEST-2 STUDY

EHA Library, Raajit K Rampal, 422325

EFFICACY AND SAFETY OF NAVITOCLAX IN COMBINATION WITH RUXOLITINIB VERSUS RUXOLITINIB PLUS PLACEBO IN PATIENTS WITH UNTREATED MYELOFIBROSIS IN THE PHASE 3 RANDOMIZED, DOUBLE-BLIND TRANSFORM-1 STUDY

EHA Library, Naveen Pemmaraju, 422326

ELRITERCEPT (KER-050) DEMONSTRATED POTENTIAL TO TREAT MYELOFIBROSIS AND MITIGATE RUXOLITINIB-ASSOCIATED CYTOPENIAS IN THE PHASE 2 RESTORE TRIAL

EHA Library, Claire Harrison, 422327

AVAPRITINIB IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS (ADVSM): EFFICACY AND SAFETY ANALYSIS FROM THE PHASE 2 PATHFINDER STUDY WITH 3-YEAR FOLLOW-UP

EHA Library, Andreas Reiter, 422328

THE RANDOMIZED STUDY GHSG HD21 SHOWS SUPERIOR TOLERABILITY AND EFFICACY OF BRECADD VERSUS BEACOPP IN ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA

EHA Library, Peter Borchmann, 422329

EORTC-1537-COBRA: VERY EARLY FDG-PET-RESPONSE ADAPTED TARGETED THERAPY FOR ADVANCED HODGKIN LYMPHOMA: A SINGLE-ARM PHASE II STUDY.

EHA Library, Martin Hutchings, 422330

SERUM TARC COMBINED WITH FDG-PET IMAGING IMPROVES INTERIM RESPONSE EVALUATION IN CLASSIC HODGKIN LYMPHOMA: A RETROSPECTIVE ANALYSIS OF GERMAN HODGKIN STUDY GROUP HD16 AND HD18 TRIALS

EHA Library, Wouter Plattel, 422331

GONADAL FUNCTION RECOVERY AND FERTILITY IN THE PHASE III GERMAN HODGKIN STUDY GROUP HD21 TRIAL

EHA Library, Justin Ferdinandus, 422332

PATIENTS WITH HISTOPATHOLOGICAL GROWTH PATTERNS D/E CONSTITUTE A HIGH-RISK GROUP IN NODULAR LYMPHOCYTE-PREDOMINANT HODGKIN LYMPHOMA: RESULTS FROM A COMPREHENSIVE GHSG ANALYSIS

EHA Library, Dennis A. Eichenauer, 422333

A PROSPECTIVE ANALYSIS OF NEWLY DIAGNOSED MANTLE CELL LYMPHOMA: PREDICTORS AND SURVIVAL OF INDOLENT DISEASE

EHA Library, Sarah Mant, 422334

GLOFITAMAB MONOTHERAPY IN PATIENTS WITH HEAVILY PRETREATED RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA: UPDATED ANALYSIS FROM A PHASE I/II STUDY

EHA Library, Tycel Phillips, 422335

PRIMARY ANALYSIS OF THE PHASE 2 ELM-2 STUDY: ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA

EHA Library, Michał Taszner, 422336

MOSUNETUZUMAB DEMONSTRATES CLINICALLY MEANINGFUL OUTCOMES IN HIGH-RISK PATIENTS WITH HEAVILY PRE-TREATED R/R FL AFTER ≥3 YEARS OF FOLLOW-UP: SUBGROUP ANALYSIS OF A PIVOTAL PHASE II STUDY

EHA Library, Sarit Assouline, 422337

EPCORITAMAB INDUCES DEEP RESPONSES IN RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): SAFETY AND POOLED EFFICACY DATA FROM EPCORE NHL‑1 PIVOTAL AND CYCLE (C) 1 OPTIMIZATION (OPT) FL COHORTS

EHA Library, Umberto Vitolo, 422338

GOLCADOMIDE (GOLCA [CC-99282]), A POTENTIAL FIRST-IN-CLASS ORAL CELMOD™ AGENT, PLUS R-CHOP IN PATIENTS (PTS) WITH UNTREATED AGGRESSIVE B-CELL LYMPHOMA (A-BCL): SAFETY AND 12-MONTH EFFICACY RESULTS

EHA Library, Marc Hoffmann, 422339

FEASIBILITY AND CLINICAL EFFICACY OF ATEZOLIZUMAB CONSOLIDATION IN HIGH RISK DIFFUSE LARGE B-CELL LYMPHOMA: FINAL ANALYSIS OF THE HOVON 151

EHA Library, Marcel Nijland, 422340

ENGLUMAFUSP ALFA (CD19/4-1BBL) COMBINED WITH GLOFITAMAB IS SAFE AND SHOWS HIGH EFFICACY IN PATIENTS WITH R/R AGGRESSIVE B-NHL: FINAL RESULTS OF THE DOSE-ESCALATION PART OF PHASE1 TRIAL BP41072

EHA Library, Franck Morschhauser, 422341

BIOMARKER-ADAPTED TREATMENT IN HIGH-RISK LARGE B-CELL LYMPHOMA: LONG-TERM FOLLOW-UP OF A NORDIC PHASE II TRIAL

EHA Library, Sirpa Leppä, 422342

FIRST DATA FROM SUBCUTANEOUS EPCORITAMAB+POLATUZUMAB VEDOTIN, RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, AND PREDNISONE (POLA-R-CHP) FOR FIRST-LINE DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): EPCORE NHL-5

EHA Library, David Lavie, 422343

EXCELLENT OUTCOME OF PATIENTS WITH RELAPSED OR REFRACTORY PRIMARY MEDIASTINAL B CELL LYMPHOMA  TREATED WITH AXICABTAGENE CILOLEUCEL : A STUDY FROM THE FRENCH DESCAR-T NATIONAL REGISTRY.

EHA Library, Jean Galtier, 422344

TRANSCAR: A REAL-LIFE OUTCOME STUDY OF RELAPSED/REFRACTORY TRANSFORMED INDOLENT NON-HODGKIN LYMPHOMA IN THE CONTEXT OF CAR T-CELLS A DESCART ANALYSIS

EHA Library, Pierre Stephan, 422345

REAL-WORLD ASSESSMENT OF ANTI-CD19 CAR-T CELLS IN PATIENTS AGED 75 YEARS AND OLDER WITH RELAPSED OR REFRACTORY LARGE B CELL LYMPHOMA: A LYSA STUDY FROM THE DESCAR-T REGISTRY

EHA Library, Blandine Guffroy, 422346

SEVEN-DAY VEIN-TO-VEIN POINT-OF-CARE–MANUFACTURED CD19 CAR T CELLS (GLPG5101) IN RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA: RESULTS FROM THE PHASE 1/2 ATALANTA-1 TRIAL

EHA Library, Marie José Kersten, 422347

AN ABBREVIATED COURSE OF A+AVD FOLLOWED BY NIVOLUMAB CONSOLIDATION FOR FRONTLINE THERAPY IN PATIENTS WITH LIMITED STAGE HODGKIN LYMPHOMA

EHA Library, Steven Park, 422348

OUTCOMES OF AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANTATION FOR T-CELL LYMPHOMA: AN UPDATED ANALYSIS OF THE EBMT LYMPHOMA WORKING PARTY

EHA Library, Evgenii Shumilov, 422349

CLINICAL IMPLICATIONS OF CTDNA IN RESIDUAL DISEASE ASSESSMENT, PROGNOSIS PREDICTION, DISEASE MONITORING FOR NEWLY PERIPHERAL T-CELL LYMPHOMA PATIENTS

EHA Library, Jin-Hua Liang, 422350

VALEMETOSTAT MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMAS: EFFICACY BY PRIOR LINES OF TREATMENT AND LAST TREATMENT OUTCOME FROM THE VALENTINE-PTCL01 STUDY

EHA Library, Pier Luigi Zinzani, 422351

THE DNA METHYLOME OF ANAPLASTIC LARGE CELL LYMPHOMA: AN LLMPP STUDY OF 404 CASES

EHA Library, Raúl F. Pérez, 422352

ENHANCED RISK STRATIFICATION IN PEDIATRIC T-CELL LYMPHOBLASTIC LYMPHOMA THROUGH INTEGRATIVE NGS, TCR STATUS, AND MDD/MRD ANALYSIS

EHA Library, Aurore Touzart, 422353

T-CELL MEDIATED STEM-LIKE PLASTICITY OF GERMINAL CENTER B CELLS

EHA Library, Laurianne Scourzic, 422354

SPATIALLY RESOLVED SINGLE-CELL PROFILING IDENTIFIES DISTINCT FOLLICULAR T-CELL SUBSETS AND ECOSYSTEMS THAT REGULATE BIOLOGICAL AND CLINICAL FATE OF FOLLICULAR LYMPHOMA

EHA Library, Yoshiaki Abe, 422355

INTEGRATED MULTI-OMIC PROFILING OF SPLENIC MARGINAL ZONE LYMPHOMA INCLUDING CASES EXPRESSING IGHV1-02*04 B-CELL RECEPTOR IMMUNOGLOBULINS

EHA Library, Amatta Mirandari, 422356

CHARACTERIZATION OF THE SUPER ENHANCER LANDSCAPE IN PRIMARY MEDIASTINAL B-CELL LYMPHOMA IDENTIFIES PIM3 AS A DRUGGABLE ONCOGENIC DEPENDENCY

EHA Library, Nazli Serin, 422357

DISTINCT EVOLUTIONARY DYNAMICS ACROSS LYMPHOID TUMORS AND ITS IMPACT ON OUTCOME

EHA Library, Martí Duran-Ferrer, 422358

DIMETHYL FUMARATE AMELIORATES CGVHD BY INHIBITING TFH DIFFERENTIATION VIA NRF2

EHA Library, Huanle Gong, 422359

ASSOCIATION OF GPR56-POSITIVE T CELL POPULATIONS AND CLINICAL OUTCOME AFTER ALLOGENEIC STEM CELL TRANSPLANTATION

EHA Library, Paul Pfitzer, 422360

THE PROTECTIVE ROLE OF CELL EXTRINSIC NRF2 IN HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH IRON OVERLOAD

EHA Library, Joana Reis, 422361

PRE-ALLOGENEIC TRANSPLANTATION FLOW CYTOMETRY TESTING FOR PATIENTS WITH AML IN FIRST CR, AS CURRENTLY PERFORMED, HAS LIMITED CLINICAL UTILITY FOR RELAPSE AND SURVIVAL PREDICTION: A CIBMTR ANALYSIS

EHA Library, Firas El Chaer, 422362

ADVANCES IN MYELOID NEOPLASMS WITH GERMLINE PREDISPOSITION: IMPACT ON DONOR RELATED ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT).

EHA Library, Amagoia Ruiz Martin, 422363

POST-TRANSPLANT CYCLOPHOSPHAMIDE-BASED GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS FOLLOWING MISMATCHED UNRELATED DONOR PERIPHERAL BLOOD STEM CELL (PBSC) TRANSPLANTATION.

EHA Library, Antonio Jimenez Jimenez, 422364

ALLOGENEIC TRANSPLANT FROM HAPLO DONORS WITH TBI VS. CHEMO FOR AML IN FIRST REMISSION. A STUDY FROM THE ACUTE LEUKEMIA WORKING PARTY OF THE EUROPEAN SOCIETY FOR BLOOD AND MARROW TRANSPLANTATION.

EHA Library, Enrico Maffini, 422365

PHASE 3 JAPANESE STUDY OF BELUMOSUDIL, A SELECTIVE ROCK2 INHIBITOR, AS SECOND OR SUBSEQUENT LOT FOR STEROID-DEPENDENT/RESISTANT CHRONIC GVHD: ANALYSIS AT 48 WEEKS AFTER THE LAST PATIENT ENROLMENT

EHA Library, Yasushi Onishi, 422366

BEAM OR CYCLOPHOSPHAMIDE IN AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANTATION FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS

EHA Library, Thomas Silfverberg, 422367

THE IMPACT OF CONDITIONING INTENSITY ON SECOND ALLOGENEIC HEMATOPOIETIC TRANSPLANTATION FOR RELAPSE AFTER FIRST TRANSPLANTATION

EHA Library, Kazuki Yoshimura, 422368

FINAL LONG-TERM FOLLOW-UP RESULTS OF THE RELAZA2 STUDY: AZACITIDINE TO TREAT MEASURABLE- RESIDUAL DISEASE IN MDS AND AML PATIENTS

EHA Library, Anne Sophie Kubasch, 422369

DEVELOPMENT AND VALIDATION OF A PROGNOSTIC MODEL FOR MIXED PHENOTYPE ACUTE LEUKEMIA PATIENTS TREATED WITH ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN A NATIONWIDE MULTICENTER STUDY

EHA Library, Xiaohui Zhang, 422370

131I-APAMISTAMAB-LED ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RESULTS IN IMPROVED SURVIVAL OUTCOMES IN R/R AML PATIENTS WITH HIGH-RISK TP53 MUTATIONS IN THE RANDOMIZED PHASE III SIERRA TRIAL

EHA Library, Hannah Choe, 422371

EARLY CARDIAC TOXICITY OCCURRING AFTER ALLO-HCT IN PATIENTS WITH ACUTE MYELOID LEUKEMIA. STUDY CONDUCTED ON BEHALF OF THE GRUPO ESPAÑOL DE TRASPLANTE HEMATOPOYÉTICO Y TERAPIA CELULAR (GETH-TC)

EHA Library, Maria Queralt Salas, 422372

CLINICAL OUTCOMES OF CHIMERISM KINETICS IN PATIENTS UNDERGOING  ALLOGENEIC STEM CELL TRANSPLANTATION USING METHOTREXATE-BASED OR POST-TRANSPLANT CYCLOPHOSPHAMIDE (PTCY) AS GVHD PROPHYLAXIS.

EHA Library, Christopher Graham, 422373

COMPARISON BETWEEN PRETRANPLANT, PERITRANSPLANT AND NO JAK INHIBITION ON OUTCOME AFTER HEMATOPOIETIC CELL TRANSPLANT FOR MYELOFIBROSIS

EHA Library, Kristin Rathje, 422374

THE IMPACT OF DIFFERENT BIOLOGICAL CHARACTERISTICS OF HIGH-RISK ACUTE MYELOID LEUKEMIA ON THE EFFICACY OF MAINTENANCE TREATMENT WITH DECITABINE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

EHA Library, Jia Liu, 422375

LISOCABTAGENE MARALEUCEL VERSUS STANDARD OF CARE WITH SALVAGE CHEMOTHERAPY FOLLOWED BY ASCT AS SECOND-LINE TREATMENT IN PATIENTS WITH R/R LARGE B-CELL LYMPHOMA: 3-YEAR FOLLOW-UP OF TRANSFORM

EHA Library, Jeremy Abramson, 422376

EXAGAMGLOGENE AUTOTEMCEL FOR SEVERE SICKLE CELL DISEASE

EHA Library, Haydar Frangoul, 422377

EXAGAMGLOGENE AUTOTEMCEL FOR TRANSFUSION-DEPENDENT ΒETA-THALASSEMIA

EHA Library, Franco Locatelli, 422378

IMPACT OF TET2 MUTATIONS ON HEMATOPOIETIC STEM CELL RESILIENCE TO IMMUNE-RELATED STRESS

EHA Library, Hector HUERGA ENCABO, 422379

TRANSCRIPTIONAL DECODING OF THE AGEING PROCESS IN THE NON-IMMUNE HUMAN BONE MARROW MICROENVIRONMENT THROUGH SINGLE-CELL AND SPATIAL TRANSCRIPTOMICS

EHA Library, Itziar Cenzano, 422380

NOCICEPTIVE NERVES FACILITATE STEM/PROGENITOR CELL HOMING TO BONE MARROW BY REGULATING MICROCIRCULATION AND MECHANOSENSING

EHA Library, Shinya Fujita, 422381

INVESTIGATING THE BIOLOGICAL PROPERTIES OF CIRCULATING HEMATOPOIETIC STEM/PROGENITOR CELLS IN PEDIATRIC SUBJECTS AS NOVEL SOURCE FOR GENE THERAPY.

EHA Library, Luca Seffin, 422382

STRUCTURAL AND FUNCTIONAL ANALYSIS OF BONE MARROW STROMAL NETWORKS DURING CHEMOTHERAPY

EHA Library, Ana Luísa Pereira, 422383

ARTIFICIAL INTELLIGENCE-POWERED MOLECULAR DOCKING FOR PROPER SCFV SELECTION OF ANTI-CD30 CHIMERIC ANTIGEN RECEPTOR (CAR)

EHA Library, Nico Martarelli, 422384

UPDATED CLINICAL RESULTS OF FIRST-IN-HUMAN STUDY OF IL-10-EXPRESSING CD19 CAR-T CELLS FOR RELAPSED/REFRACTORY B-CELL HEMATOLOGICAL MALIGNANCIES

EHA Library, Qianwen Xu, 422385

PREDICTING THERAPY-RELATED MYELOID NEOPLASMS AFTER CAR-T: VALIDATION OF THE CLONAL HEMATOPOIESIS RISK SCORE (CHRS)

EHA Library, Eugenio Galli, 422386

IMPROVING CAR-T CELL FUNCTION THROUGH A TARGETED CYTOKINE DELIVERY SYSTEM UTILIZING CAR TARGET-MODIFIED EXTRACELLULAR VESICLES

EHA Library, Meijuan Huang, 422387

BASE EDITING-MEDIATED, IN VIVO INDUCTION OF -113 A>G HPFH MUTATION, EFFICIENTLY REACTIVATES HBF EXPRESSION IN HUMANIZED MOUSE MODELS OF Β-HEMOGLOBINOPATHIES

EHA Library, Kiriaki Paschoudi, 422388

RENI-CEL, THE FIRST ASCAS12A GENE-EDITED CELL THERAPY, LED TO HEMOGLOBIN NORMALIZATION AND INCREASED FETAL HEMOGLOBIN IN SEVERE SICKLE CELL DISEASE PATIENTS IN AN INTERIM ANALYSIS OF THE RUBY TRIAL

EHA Library, Rabi Hanna, 422389

SAFETY AND EFFICACY OF ARMORED HUCART19-IL18 IN PATIENTS WITH RELAPSED/REFRACTORY LYMPHOMAS WHO PROGRESSED AFTER ANTI-CD19 CAR T-CELL THERAPY.

EHA Library, Jakub Svoboda, 422390

HIGH EFFICACY AND SAFETY OF INTERLEUKIN-6-KNOCKDOWN CD19-TARGETED CAR T CELLS IN RELAPSED/REFRACTORY B-ALL PATIENTS

EHA Library, lei yu, 422391

EFFICACY AND TOXICITY OF ANTI-CD19 CAR T-CELLS IN PATIENTS WITH PRIMARY AND SECONDARY CNS-LYMPHOMA – AN ANALYSIS OF THE LYMPHOMA WORKING PARTY OF THE EBMT AND THE GOCART COALITION

EHA Library, Anna Ossami Saidy, 422392

INTERIM ANALYSIS OF THE PHASE I SAFETY RUN IN COHORT OF THE MONOCENTRIC “CD19.CAR-T CELLS IN SYSTEMIC B CELL-MEDIATED AUTOIMMUNE DISEASE” (CASTLE) STUDY

EHA Library, Fabian Müller, 422393

AZATHIOPRINE/HYDROXYUREA PRECONDITIONING PRIOR TO NON-MYELOABLATIVE MATCHED SIBLING DONOR HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH SICKLE CELL DISEASE: A PROSPECTIVE OBSERVATIONAL COHORT STUDY

EHA Library, Elisabeth Dovern, 422394

PRELIMINARY RESULTS FROM A MULTICENTER PHASE 2/3 STUDY OF NEXT-GENERATION HBS POLYMERIZATION INHIBITOR OSIVELOTOR (GBT021601) FOR THE TREATMENT OF PATIENTS WITH SICKLE CELL DISEASE

EHA Library, Santosh Saraf, 422395

POSTERIOR CEREBRAL CIRCULATION IN CHILDREN WITH SICKLE CELL DISEASE: AN UNCHARTED TERRITORY

EHA Library, Giulia Reggiani, 422396

HYDROXYCARBAMIDE & HYPERTRANSFUSION PRE-CONDITIONING LEADS TO HIGH RATES OF CURE & ABROGATES GRAFT FAILURE IN REDUCED INTENSITY PTCY HAPLOIDENTICAL TRANSPLANTATION IN CHILDREN WITH SICKLE CELL DISEASE

EHA Library, Josu de la Fuente, 422397

INTERIM RESULTS OF A PHASE 1B STUDY (PIONEER) OF AN ORAL HBF INDUCER, POCIREDIR, IN SICKLE CELL DISEASE

EHA Library, Caterina Minniti, 422398

TREATMENT OF PATIENTS WITH SEVERE TRANSFUSION-DEPENDENT Β-THALASSEMIA WITH CS-101, AN AUTOLOGOUS, EX VIVO EDITED, CD34+ HEMATOPOIETIC STEM CELL PRODUCT USING INNOVATIVE TRANSFORMER BASE EDITOR (TBE)

EHA Library, Lijie Wang, 422399

SPLENECTOMY AND Β-THALASSEMIA IN FRANCE : BENEFITS, RISKS AND PRACTICES

EHA Library, Audrey Benoit, 422400

SOVLEPLENIB FOR THE TREATMENT OF WARM ANTIBODY AUTOIMMUNE HEMOLYTIC ANEMIA (WAIHA): RESULTS FROM THE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 PART OF THE STUDY

EHA Library, Fengkui Zhang, 422401

REPURPOSING OF SPIRONOLACTONE AS NLRP1 INHIBITOR FOR THE TREATMENT OF DIAMOND-BLACKFAN ANEMIA

EHA Library, Juan M Lozano-Gil, 422402

EX VIVO PYRUVATE KINASE ACTIVATION IN HEREDITARY SPHEROCYTOSIS AND XEROCYTOSIS: IMPROVED ENZYME FUNCTION AND RED CELL PROPERTIES.

EHA Library, Jonathan de Wilde, 422403

SERUM IRON VARIATION IS CIRCADIAN-REGULATED AND LINKED TO THE HARMONIC CIRCADIAN OSCILLATIONS OF ERYTHROPOIESIS AND HEPATIC TFRC EXPRESSION IN MICE.

EHA Library, Cavan Bennett, 422404

HEMATOPOIETIC TFR2 DELETION CAUSES A METABOLIC HYPERACTIVATION OF ERYTHROID CELLS

EHA Library, Simona Maria Di Modica, 422405

REDUCED FERRITIN AND INCREASED BONE SPECIFIC ALKALINE PHOSPHATASE IN PARTICIPANTS WITH LOWER-RISK MDS TREATED WITH ELRITERCEPT (KER-050) SUPPORT POTENTIAL TO REBALANCE THE OSTEOHEMATOPOIETIC NICHE

EHA Library, David Valcárcel, 422406

ADDITIVE EFFECT OF MULTIPLE GENETIC VARIANTS IN SEC23B-PIEZO1 ON IRON METABOLISM DYSHOMEOSTASIS IN HEREDITARY ANEMIAS

EHA Library, Antonella Nostroso, 422407

TARGETING THE HEPCIDIN INHIBITOR TMPRSS6 COUNTERACTS METABOLIC LIVER DISEASE AND ITS COMPLICATIONS

EHA Library, Laura SILVESTRI, 422408

CMV/EBV INFECTIONS IN CAR-T THERAPY FOR RELAPSED/REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA

EHA Library, Jing Pan, 422409